Presenting author

Ramakrishna Nirogi

1 presentation

• T48. Ropanicant (SUVN-911), an α4β2 nAChR antagonist: A phase 2b, randomized, double-blind, placebo-controlled, parallel-group study, evaluating the efficacy and safety of ropanicant in patients with major depressive disorder (MDD)

  2026 ASCP Annual Meeting